Richard Binstein - May 16, 2024 Form 4 Insider Report for U S PHYSICAL THERAPY INC /NV (USPH)

Role: EVP Gen'l Counsel & Secretary
Signature: /s/ Rick S. Binstein
Stock symbol: USPH
Transactions as of: May 16, 2024
Transactions value $: -$224,484
Form type: 4
Date filed: 5/17/2024, 04:54 PM
Previous filing: Mar 14, 2024
Next filing: Nov 26, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	USPH	Common Stock	Disposed to Issuer	-$224K	-2.11K	-14.07%	$106.34	12.9K	May 16, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported ($106.34) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $106.03 to $106.78 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2	Includes 12,895 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,239 shares on each of July 1, 2024 and October 1, 2024; 1,241 shares on January 1, 2025; 1,045 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 1,049 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.

Content

The price reported ($106.34) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $106.03 to $106.78 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Includes 12,895 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,239 shares on each of July 1, 2024 and October 1, 2024; 1,241 shares on January 1, 2025; 1,045 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 1,049 shares on January 1, 2026; 740 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 747 shares on January 1, 2027; and 506 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 507 shares on January 1, 2028, if he is an employee of the Company on those dates.